Last reviewed · How we verify

Ciprofloxacin DPI (BAYQ3939) — Competitive Intelligence Brief

Ciprofloxacin DPI (BAYQ3939) (Ciprofloxacin DPI (BAYQ3939)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoroquinolone antibiotic. Area: Infectious Disease.

phase 3 Fluoroquinolone antibiotic DNA gyrase, Topoisomerase IV Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Ciprofloxacin DPI (BAYQ3939) (Ciprofloxacin DPI (BAYQ3939)) — Bayer. Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ciprofloxacin DPI (BAYQ3939) TARGET Ciprofloxacin DPI (BAYQ3939) Bayer phase 3 Fluoroquinolone antibiotic DNA gyrase, Topoisomerase IV
besivance besivance Ophthalmology Consultants, Ltd. marketed DNA gyrase, Topoisomerase IV
Renamezin capsule Renamezin capsule Daewon Pharmaceutical Co., Ltd. marketed Fluoroquinolone antibiotic DNA gyrase, Topoisomerase IV
Ciprofloxacin 0.3% Ciprofloxacin 0.3% Indiana University School of Medicine marketed Fluoroquinolone antibiotic DNA gyrase, topoisomerase IV
Ciprofloxacin Tablets & Metronidazole tablets Ciprofloxacin Tablets & Metronidazole tablets MinaPharm Pharmaceuticals marketed Fluoroquinolone + Nitroimidazole antibiotic combination Bacterial DNA gyrase, topoisomerase IV (ciprofloxacin); anaerobic DNA (metronidazole)
ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin University of British Columbia marketed Fluoroquinolone, Sulfonamide-diaminopyrimidine combination, Nitrofuran Bacterial DNA gyrase, topoisomerase IV, dihydrofolate reductase, bacterial DNA
moxifloxacin / dexamethasone moxifloxacin / dexamethasone Federal University of São Paulo marketed Fluoroquinolone antibiotic + corticosteroid combination Bacterial DNA gyrase, topoisomerase IV, glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fluoroquinolone antibiotic class)

  1. Bayer · 4 drugs in this class
  2. Allergan · 4 drugs in this class
  3. Mackay Memorial Hospital · 2 drugs in this class
  4. Indiana University School of Medicine · 2 drugs in this class
  5. Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 drug in this class
  6. Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
  7. Connect Biopharma Australia Pty Ltd · 1 drug in this class
  8. GlaxoSmithKline · 1 drug in this class
  9. Global Alliance for TB Drug Development · 1 drug in this class
  10. Fundacion Clinic per a la Recerca Biomédica · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ciprofloxacin DPI (BAYQ3939) — Competitive Intelligence Brief. https://druglandscape.com/ci/ciprofloxacin-dpi-bayq3939. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: